Odyssey Long Term Trial - Dr. Milan Chag
Channel: Marengo CIMS Hospital
Date: 11/04/2016

Dr. Milan Chag, Cardiologist from CIMS Hospital(Ahmedabad) discussess ODYSSEY Long Term trial in this video.Alirocumab is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor monoclonal antibody for the treatment of heterozygous familial hypercholesterolemia, or patients with atherosclerotic heart disease who require additional lowering of LDL-cholesterol. Over a period of 78 weeks, Alirocumab, when added to statin therapy (at maximum tolarated dose), significanly reduced LDL cholestrol level.In a post hoc analysis, there was evedence of significant reduction in the rate of CV events.